Engagement included coordination with other shareholders. Robert Naylor joined the board in early November 2025.
Post period end, British Land announced a recommended cash and share offer for Life Science, valuing the shares at approximately 42.8 pence per share at announcement. The 31 December 2025 close of 39.4 pence implies only a modest uplift versus the entry price of 38.9 pence. The Company owned a maximum of 13,000,000 ordinary shares during the period, being 3.71% of Life Science’s issued share capital. At the period end, the Company owned 13,000,000 ordinary shares.
The information on this website is solely for information purposes and is not intended to be, and should not be construed as, an offer or recommendation to buy and sell investments. If you are in any doubt as to the appropriate course of action, we would recommend that you consult your own independent financial adviser, stockbroker, solicitor, accountant or other professional adviser.
Past performance is no guide to the future. The value of investments and the income from them may go down as well as up and investors may not get back the full amount they originally invested. The information herein has been obtained from sources believed to be reliable but no representation or warranty is given or may be implied that they are accurate or complete.
By entering the Achilles Investment Company Website you agree that you have read, understood and accepted the above.